Posted by Michael Wonder on 01 Oct 2019
Symbicort Turbuhaler now approved by Health Canada for use in mild persistent, moderate, or severe asthma
30 September 2019 - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort Turbuhaler (budesonide/formoterol) for the treatment of mild persistent asthma in patients 12 years and older.
Symbicort Turbuhaler is now approved as an anti-inflammatory reliever in Canada for use in mild persistent, moderate, or severe asthma patients.
The approval was based on positive results from the Phase III SYGMA 1 and 2 trials, published in the New England Journal of Medicine, which evaluated the efficacy of Symbicort Turbuhaler taken only as-needed as an anti-inflammatory reliever versus current standard of care therapies in mild asthma.
